Elevated serum fibrin-monomer levels are associated with high long-term cerebrovascular event rates in acute ischemic stroke patients

Circ J. 2007 Oct;71(10):1573-9. doi: 10.1253/circj.71.1573.

Abstract

Background: Serum fibrin-monomer (FM) is a precursor of stable fibrin, and is a sensitive marker of a systemic hypercoagulable state. It has been reported that, in patients with acute ischemic stroke, higher levels of serum FM reflect intracardiac thrombus formation.

Methods and results: Serum coagulation and fibrinolytic activity were measured in 113 patients with acute ischemic stroke within 7 (6+/-1) days after onset. The patients were followed for a mean of 354 (range 36-585) days. The primary endpoints were ischemic stroke recurrence with/without death. FM was markedly higher in the 19 cases with stroke recurrence (49.6+/-53.6 microg/ml) than in the 94 patients without stroke recurrence (14.6+/-30.5 microg/ml; p=0.008). The cerebrovascular event rates were markedly higher in the 12 cases with FM > or =16.5 microg/ml (37.5%) than in the 7 cases with FM <16.5 microg/ml (8.6%; p<0.001). Cox proportional hazards multivariate analysis showed that the FM level was an independent predictor of ischemic stroke recurrence with/without death (hazard ratio, 1.516 per + 1 standard deviation increase; 95% confidence interval, 1.042-2.180; p=0.036).

Conclusions: Elevated serum FM levels in hospitalized ischemic stroke patients may be associated with a persistent systemic hypercoagulable state and high long-term rates of cerebrovascular events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Brain Ischemia / blood*
  • Echocardiography, Transesophageal
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Recurrence
  • Risk Factors
  • Stroke / blood*
  • Stroke / diagnosis*
  • Thrombophilia

Substances

  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • fibrinmonomer